A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Patients at High Risk of Severe Forms of Covid-19
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 4,235
- 试验地点
- 2
- 主要终点
- Mortality rate
研究概览
简要总结
Absence of anti-SARS-CoV-2 vaccine response or insufficient vaccine response may occur in immunocompromised patients. Being at high risk of a severe form of Covid-19, they may be eligible to receive recombinant anti-SARS-CoV-2 monoclonal antibodies (mAbs). This study aims to describe patients who received anti-SARS-CoV-2 mAbs, in prophylaxis and/or curative of covid-19, and to analyze the hospitalization and mortality rates. This study is multicentric on all the university hospitals of Paris (AP-HP).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult ≥ 18 years old
- •Patients who received at least one administration of the following therapies: casirivimab-imdevimab, bamlanivimab-etesevimab, tixagevimab-cilgavimab, regdanvimab, sotrovimab or adintrevimab
排除标准
- •Patients opposed to the collection of their personal data
研究组 & 干预措施
Patients who have received an anti-SARS-CoV-2 monoclonal antibody
Patients who have received an anti-SARS-CoV-2 monoclonal antibody, either prophylactically or curatively.
干预措施: Data collection (Other)
结局指标
主要结局
Mortality rate
时间窗: 29 days after last administration
Covid-19 mortality : Explore the mortality rate related to COVID-19 in patients treated with anti-SARS-CoV-2 monoclonal antibodies
次要结局
- Hospitalizations rate(90 days after last administration)
- Proportion of deaths(90 days after last administration)
- Proportion of hospitalizations(90 days after last administration)
- Mortality rate(90 days after last administration)
- Hospitalizations rate(29 days after last administration)
- Mortality rate(29 days after last administration)
- Proportion of hospitalizations(29 days after last administration)
- Proportion of deaths(29 days after last administration)